9.5 million people die from drug resistant cancers every year.
We start research where other therapies fail.
Creative BioTherapeutics discovers treatments for patients with incurable diseases.
We at Creative BioTherapeutics are changing the way that cancer and viral disease research is conducted. CBT focuses on the root cause of cancer effecting immune evasion and drug resistance. We target the tough stuff, the types of cancers that make people lose hope, the kind that comes back.
We have discovered promising
treatments for adult and
childhood cancers showing
tumor regression and
potential cures.
Our Focus
Brain Cancer
A leading Cause of death in children. Children with brain cancer are not expected to live past a year.
Metastatic Breast Cancer
A leading cause of death in women. Most patients with lung and metastatic breast cancers have a 5-year survival rate of less than 25%.
COVID-19
Currently resulting in over 1 million deaths in the US.
Emerging biotech,
Creative BioTherapeutics, LLC
Receives a Phase II
National Science Foundation
Small Business Innovation
Research Award
Gurnee, Illinois, April 2022-Creative BioTherapeutics LLC (CBT) was granted a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II award for $990,000 in support of the clinical development of its Novel Anti-viral Technology. This anti-viral technology can revert the COVID-19 infected and stressed lung cells to a non-infected, normal state. The mechanism of action of CBT’s lead anti-viral therapy blocks all variants of concern for COVID-19 since it protects normal cells from virus infection. This emerging, pre-clinical therapy has also been shown to be effective for multiple viruses including Ebola and Influenza.
Creative BioTherapeutics (CBT) was awarded and successfully completed a Phase I NSF SBIR grant in 2021. The Phase I grant was awarded to only 1% of applicants (20,000 applicants) and the Phase II grant is awarded to less than 50% of Phase I recipients that apply. This award is highly prestigious with only 1,200 awarded over the past 20 years. The review process is extremely rigorous involving full scientific, business, and financial reviews in order to ensure that the awarded company has the team and resources to move aggressively toward the market. CBT is awarded this very elite and prestigious grant to continue to move the lead anti-viral drug toward clinical trials and commercialization with a goal of market entry in 2024. After receiving the Phase II award, CBT is now eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
“This Phase II grant is an exciting opportunity for CBT to more quickly move our therapy toward commercialization to provide hope and potential return to health for patients with late-stage COVID-19 or other viral diseases that otherwise could lead to death. As a company, we target difficult to treat diseases where there are few available options. We are very excited to continue our work with the NSF” says Dr. Anita Davidson, Co-Founder/President.
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov.
Creative BioTherapeutics, LLC Awarded Competitive Grant
from the National Science Foundation Small Business Innovation Research Program Provides Seed Funding for R&D
Gurnee, Illinois, January 2021-Creative BioTherapeutics LLC was awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research and development (R&D) work on Development of a Novel Therapy for the Treatment of COVID-19.
Creative BioTherapeutics (CBT) has discovered that a viral infection stresses the body similarly to the way that comorbidities such as cancer create stress. COVID-19 infection causes the patient to deteriorate more quickly as a result of these conditions by placing enormous stress on the cells making them more susceptible to virus infection and COVID-19 related death. To solve these issues, CBT has created a novel and ground breaking therapy to reduce cellular stress, block virus infection and increase survival for late-stage COVID-19 patients.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
“When we identified the way that viruses infect and compared this information to how our cancer therapies work, we realized that we had an exciting opportunity to reduce the negative impact from COVID-19 disease and save lives. This therapy could stop future pandemics by understanding how the virus infects the body.”
Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II grant (up to $1,000,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
Startups or entrepreneurs who submit a three-page Project Pitch will know within three weeks if they meet the program’s objectives to support innovative technologies that show promise of commercial and/or societal impact and involve a level of technical risk. Small businesses with innovative science and technology solutions, and commercial potential are encouraged to apply. All proposals submitted to the NSF SBIR/STTR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. To learn more about America’s Seed Fund powered by NSF, visit: https://seedfund.nsf.gov/
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering.